Revvity, Inc. — News

RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.

zacks.com - 2026-07-24 12:05:19

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies.

businesswire.com - 2026-07-23 08:00:00

RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.

zacks.com - 2026-07-22 12:05:14

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies adopt scalable informatics capabilities earlier in their growth journey. Built for early-stage biotechs, the program combines access to enterprise-grade Signals software with guided onboarding and best-practice configurations tailored specifically for smaller biotechs to help accelerate innovation,.

businesswire.com - 2026-07-20 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company's sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations. "At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Sin.

businesswire.com - 2026-07-20 08:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of.

businesswire.com - 2026-07-08 08:00:00

RVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.

zacks.com - 2026-07-02 11:01:15

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropic's new AI workbench for scientific research. As organizations increasingly adopt artificial intelligence to accelerate scientific research, the challenge is ensuring AI mo.

businesswire.com - 2026-07-01 08:00:00

RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.

zacks.com - 2026-06-23 09:50:33

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. As scientific organizations generate increasing volumes of data acr.

businesswire.com - 2026-06-22 08:00:00

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 10:52:14

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-04 12:35:53

Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

zacks.com - 2026-05-14 13:01:11

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 15:10:48

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.

businesswire.com - 2026-05-13 08:00:00

Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.

zacks.com - 2026-05-05 11:41:07

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-05 11:01:13

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-05-05 10:30:40

Revvity (RVTY) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago.

zacks.com - 2026-05-05 08:45:27

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the quarter was $711 million, as compared to $665 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $76 million, as compared to $72 million for the same perio.

businesswire.com - 2026-05-05 06:00:00

RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.

zacks.com - 2026-05-04 09:50:59

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from dis.

businesswire.com - 2026-04-30 16:05:00